Article Text
PDF
Abstract
BACKGROUND It has been reported that pranlukast reduces the antigen induced immediate and late phase asthmatic responses, airway hyperreactivity to acetylcholine, and pulmonary eosinophil accumulation in guinea pigs. A study was undertaken to test the hypothesis that pranlukast may reduce the number of inflammatory cells in the bronchial mucosa of patients with asthma.
METHODS A double blind, placebo controlled study was performed in 17 mild to moderate asthmatic subjects to examine changes in inflammatory cell infiltration in response to pranlukast (225 mg orally twice per day for four weeks). Comparisons of the mean daily β2 agonist use, symptom score, FEV1 percentage predicted, and airway methacholine responsiveness were made before and after treatment. Using fibreoptic bronchoscopy, bronchial biopsy specimens were obtained before and after treatment with either pranlukast (n = 10) or placebo (n = 7). Immunohistology was performed using monoclonal antibodies for CD3, CD4, CD8, CD68, NP57, AA1, EG1, EG2, γGTP and CD19.
RESULTS When the pranlukast and placebo treated groups were compared there were decreases in β2agonist use, symptom score, and airway methacholine responsiveness after pranlukast but no increase in FEV1 was seen. The clinical response in patients treated with pranlukast was accompanied by a reduction in CD3 (median difference –37, 95% confidence interval (CI) –69 to –1; p<0.05), CD4 (median difference –28, 95% CI –49 to –8; p<0.01), AA1 (median difference –15, 95% CI –26 to 0; p<0.05) and EG2 positive cells (95% CI –35 to 0; p<0.05), but not in EG1 positive eosinophils, γGTP positive cells, and CD19 positive plasma cells.
CONCLUSIONS These results support the view that pranlukast may act by inhibition of bronchial inflammation in patients with asthma.
- leukotriene receptor antagonist
- asthma
- pranlukast